The Wyss Center for Bio and Neuroengineering Geneva announced the successful closing of the seed financing round of Clee Medical SA, a Swiss neurotechnology spin-off developing ultra-high-resolution real-time intraoperative imaging for brain surgery.
The round was led by High-Tech Gründerfonds, with participation from Zürcher Kantonalbank, Kickfund, FONGIT, and Venture Kick. Existing investor Wyss Center Geneva also joined the round.
Clee Medical spun out of Wyss Geneva’s Minimally Invasive Intracranial Access research project in December 2024. The company’s flagship platform, Neuro Access, combines optical coherence tomography imaging with advanced navigation to enable neurosurgeons to visualize brain anatomy and critical structures in real time during stereotactic procedures.
Today, most brain surgeries rely on scans taken before an operation begins. However, once surgery is underway, the brain can shift, making pre-operative images less reliable. Neuro Access is designed to address this challenge by providing a live, high-resolution view during surgery. The system uses a slender probe no wider than instruments already used in common brain procedures, allowing it to integrate into existing surgical workflows without requiring new techniques or equipment. The platform is designed to identify critical structures, including blood vessels, before they are reached, reducing the risk of accidental damage and supporting safer, minimally invasive procedures.
The seed funding will support Clee Medical’s transition from research into clinical validation. The company plans to further develop the Neuro Access platform, conduct an initial study with human patients, and complete the regulatory steps required to bring the product to market.
Clee Medical, founded in 2024 and based in Geneva, was named one of the Top 100 Swiss Startups in 2025. The company continues to receive backing from the Wyss venture ecosystem.
Wyss Geneva is an independent, not-for-profit neuro venture builder focused on advancing treatments for neurological and mental health disorders. Established in 2014 with the support of Swiss entrepreneur and philanthropist Hansjörg Wyss, the organization operates at the intersection of artificial intelligence, bioengineering, and neuroengineering.
KEY QUOTES
“Clee Medical not only holds the promise of improving patient outcomes but also highlights Wyss Geneva’s dedication to bridging the gap between scientific discovery and real-world impact.”
Dr. Erwin Böttinger, CEO, Wyss Geneva
“Neurosurgery still relies heavily on pre-operative imaging, while the reality in the operating room is dynamic and uncertain. This Seed round allows us to bring a new level of real-time visibility into the brain, supporting safer procedures and expanding what minimally invasive neurosurgery can achieve.”
Matthew Lapinski, Co-Founder And CEO, Clee Medical SA
